AI reads faces and voices to spot Parkinson's
NCT ID NCT07392411
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether artificial intelligence can help diagnose Parkinson's disease by analyzing facial expressions and speech patterns. Researchers will record videos of 720 participants, including people with Parkinson's and similar conditions, as well as healthy volunteers. The goal is to develop a digital tool that could make diagnosis faster and more objective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a new, non-invasive digital tool to help doctors diagnose Parkinson's disease and related conditions earlier and more accurately.
- What could go wrong
- This is an early-stage study focused on developing and testing the AI model. The technology may not prove accurate enough for real-world use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY CONTROL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
首都医科大学附属北京天坛医院
RECRUITINGBeijing, Beijing Municipality, 100070, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Can brain stimulation sharpen Decision-Making in Parkinson's?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- Can Stem-Cell implants restore movement in Parkinson's?
- Can an experimental pill slow a rare brain disease? a trial puts ATH434 to the test.